Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine

被引:20
|
作者
Kandasamy, Mani [1 ]
Srinivas, P. [2 ]
Subramaniam, Kala [3 ]
Ravi, Sandhya [3 ]
John, James [3 ]
Shekar, Radha [2 ]
Srinivas, Nuggehally [4 ]
Thangam, Saral [3 ]
机构
[1] Lotus Labs, Biometr, Bangalore, Karnataka, India
[2] Lotus Labs Pvt Ltd, Bioanalyt, Bangalore, Karnataka, India
[3] Lotus Labs Pvt Ltd, Clin, Bangalore, Karnataka, India
[4] Suramas Biopharm, Drug Dev, Bangalore, Karnataka, India
关键词
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability; CYTOCHROME-P450; 2D6; GENOTYPE; PHARMACOKINETICS; ANTIDEPRESSANT; DISPOSITION; POOR; POLYMORPHISM; ENANTIOMERS; WY-45,030;
D O I
10.1007/s00228-010-0829-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Venlafaxine (VEN), a well accepted anti-depressant, is metabolized through the cytochrome P 450 (CYP) 2D6 isozyme to form O-desmethyvenlafaxine (ODV). Due to the involvement of CYP2D6, the formation of ODV is influenced by genetic polymorphism. We used standard tools of assessment to explore the phenotypic distribution in a retrospective manner using the pharmacokinetic (PK) data of VEN and ODV obtained from several bioavailability/bioequivalence (BA/BE) studies in healthy subjects using the reference formulation. Four single oral dose, open-label, randomized crossover BA/BE studies of VEN (doses: 37.5-150 mg) were performed in 141 healthy subjects. Plasma samples were collected over a period 72 h post VEN administration. The samples were analyzed for VEN and ODV using a validated LC/MS/MS assay with a limit of quantification 2.073 ng/mL for VEN and 3.973 ng/mL for ODV. PK parameters (C-max, T-max, AUC (0-t), AUC(0-a), t(1/2)) were computed using the noncompartmental approach. AUC metabolic ratios of VEN/ODV and ODV/VEN were computed for all subjects and were subjected to normality test procedures to tease out phenotypic distribution. ODV/VEN and VEN/ODV AUC metabolic ratios were evaluated for standard normal distribution and outliers to determine phenotypic distribution. Use of the VEN/ODV AUC metabolic ratio, arranged in a rank order, resulted in a distribution that distinguished poor metabolizers (PM) and extensive metabolizers (EM). The application of the ODV/VEN AUC metabolic ratio showed a unique distribution that distinguished ultra metabolizers (UM) and extensive metabolizers. By using both metabolic ratios, 141 healthy subjects were classified as follows: PMs = 18, EMs = 118, UMs = 5. Regardless of the formulation or dose size used, the plasma concentration-time profiles for both VEN and ODV were distinct amongst the three phenotypes identified in this work. The use of VEN/ODV and ODV/VEN AUC metabolic ratios suggested quantitative differences. The data support the use of ODV/VEN but not VEN/ODV metabolic ratio for the identification of UM phenotypes of VEN. The derived metabolic ratios of ODV/VEN from this work were in line with other studies that used both phenotypic and genotypic correlation strategies for VEN.
引用
收藏
页码:879 / 887
页数:9
相关论文
共 50 条
  • [1] Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine
    Mani Kandasamy
    P. Srinivas
    Kala Subramaniam
    Sandhya Ravi
    James John
    Radha Shekar
    Nuggehally Srinivas
    Saral Thangam
    European Journal of Clinical Pharmacology, 2010, 66 : 879 - 887
  • [2] Association between CYP2D6 genotype and venlafaxine and O-desmethylvenlafaxine concentrations and efficacy: Results from two French studies
    Konecki, C.
    Colle, R.
    Chappell, K.
    Tayeb, A. E. K. Ait
    Becquemont, L.
    Corruble, E.
    Verstuyft, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 41 - 42
  • [3] The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort
    Kringen, Marianne K.
    Braten, Line S.
    Haslemo, Tore
    Molden, Espen
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 137 - 144
  • [4] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    M. Hermann
    M. Hendset
    K. Fosaas
    M. Hjerpset
    H. Refsum
    European Journal of Clinical Pharmacology, 2008, 64 : 483 - 487
  • [5] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    Hermann, M.
    Hendset, M.
    Fosaas, K.
    Hjerpset, M.
    Refsum, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (05) : 483 - 487
  • [6] INCREASED SUM CONCENTRATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AND RISK OF SIDE EFFECTS IN COMBINED CYP2D6/CYP2C19 POOR METABOLIZERS
    Kringen, M. K.
    Haslemo, T.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 6
  • [7] Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype
    Mannheimer, Buster
    Haslemo, Tore
    Lindh, Jonatan D.
    Eliasson, Erik
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2016, 38 (01) : 127 - 134
  • [8] Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
    Haslemo, Tore
    Eliasson, Erik
    Jukic, Marin M.
    Ingelman-Sundberg, Magnus
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (01) : 194 - 201
  • [9] Correlation between CYP2D6 geno-and phenotypes with clinical outcomes under antidepressant treatment with venlafaxine
    Shams, M
    Arneth, B
    Lackner, K
    Hiemke, C
    Haertter, S
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S339 - S340
  • [10] Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
    L Karlsson
    A-L Zackrisson
    M Josefsson
    B Carlsson
    H Green
    F C Kugelberg
    The Pharmacogenomics Journal, 2015, 15 : 165 - 171